Epsilico
Curated by SignalGenerative AI technology for designing biologics
Overview
Generative AI technology for designing biologics. The platform leverages generative AI to create biopharmaceuticals for hard-to-drug targets such as GPCRs, secreted proteins, ion-channels, and transporter proteins. It combines hypothesis-driven engineering, an AI protein design pipeline, and laboratory automation to design the 3D structure of therapeutic proteins that can bind to selected drug targets. Its geometrical deep learning models are used to tailor the shapes of the proteins to suit distinct drug-target families and for optimal performance in therapeutic applications.
Key facts
- Founded
- 2021
- Headquarters
- Berlin, Germany
- Stage
- Sign up to view
- Industry
- High Technology
Contact
- Sign up to view
- Phone
- Sign up to view